source
- CRISPR Therapeutics to test highest dose of lipid‑lowering gene editing therapy after mixed durability dataCRISPR Therapeutics presented early‑stage data at the European Society of Cardiology meeting showing that its lipid‑lowering gene editing candidate produced mixed durability results a year after pa…
- Roche commits over $1 billion to DualityBio for ADC development targeting TOP1 resistanceRoche's Genentech unit announced a major investment in DualityBio to advance antibody-drug conjugate (ADC) technology. Under the agreement DualityBio will receive an upfront payment of $45 million…